Exchange: BATS·Updated 07:59 PM EDT

ARKG News

News
all
press releases
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.
Stocktwits
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
The trades put some of Ark's better-known holdings on the sell side, including AMD, Alphabet, and SpaceX, while its genomics-focused ARK Genomic Revolution ETF continued to add to biotech companies.
Stocktwits
More News
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.
Stocktwits
Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
Twist’s Lilly agreement and involvement in Anthropic research highlight its role in building and testing AI-designed proteins.
Stocktwits
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Stocktwits
CMPS Stock Rallies On Launch-Prep Push Ahead Of FDA Psychedelics Hearing
Compass has said a rolling FDA application is already underway for its COMP360, with the package due to be completed in the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027.
Stocktwits
What Is Cathie Wood Buying Now? Nvidia, SpaceX And Crypto Stocks Led ARK’s August Trades – While Cutting These Growth Stocks
Nvidia was ARK’s biggest August purchase, with roughly 548,000 shares added during the month.
Stocktwits
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Stocktwits
CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics
The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.
Stocktwits
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.
Stocktwits
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders
ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.
Stocktwits

Advertisement|Remove ads.